{
    "clinical_study": {
        "@rank": "132708", 
        "arm_group": [
            {
                "arm_group_label": "Vildagliptin 50mg once daily (QD)", 
                "arm_group_type": "Active Comparator", 
                "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"
            }, 
            {
                "arm_group_label": "Vildagliptin 50mg twice daily (BID)", 
                "arm_group_type": "Active Comparator", 
                "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to observe change of HbA1c over time from baseline to month 12.\n       The ultimate goal of this study is to provide a local reference value to the physicians &\n      patients in the future when they consider initiating Vildagliptin and taking balance between\n      efficacy, compliance, risk factors, convenience and medication cost."
        }, 
        "brief_title": "Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type-2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or Female in age \u226518 at Visit 1\n\n          2. Type 2 diabetes mellitus (T2DM) patients on their maximum tolerated dose of Metformin\n             for more than 3 months\n\n          3. HbA1c (glycosylated hemoglobin) at Visit 1 greater than 7.0%\n\n          4. With nearest documented record of HbA1c before Visit 1 greater than 7.0% after\n             patient reached his/her maximum tolerated dose of Metformin\n\n        Exclusion Criteria:\n\n          1. Patients with hepatic impairment, including patients with a pre-treatment alanine\n             aminotransferase (ALT) or aspartate aminotransferase (AST)  > 2.5 X the upper limit\n             of normal at Visit 1\n\n          2. Patients with moderate or severe renal impairment or end-stage-renal-disease (ESRD)\n             on haemodialysis at the time of enrolment\n\n          3. Patients with hereditary problems of galactose intolerance, the Lapp lactose\n             deficiency or glucose-galactose malabsorption\n\n          4. Pregnant women or breastfeeding women at the time of enrolment\n\n          5. Use of insulin or other oral anti-diabetic drug (OAD) apart from Metformin in the\n             past for T2DM treatment\n\n        Other protocol defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766778", 
            "org_study_id": "CLAF237AHK01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Vildagliptin 50mg once daily (QD)", 
                    "Vildagliptin 50mg twice daily (BID)"
                ], 
                "description": "Vildagliptin 50mg capsule", 
                "intervention_name": "Vildagliptin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Galvus", 
                    "LAF237"
                ]
            }, 
            {
                "arm_group_label": [
                    "Vildagliptin 50mg once daily (QD)", 
                    "Vildagliptin 50mg twice daily (BID)"
                ], 
                "description": "Metformin maximum tolerance dose", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vildagliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "type-2 diabetes mellitus, inadequately controlled Metformin", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong SAR", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "HongKong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Hong Kong"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Local Phase IV, Multicenter, Open-label Study to Evaluate Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To examine the change in HbA1c from baseline to month12 for patients administered with Vildagliptin (50mg once daily or 50 mg twice daily) add-on regimen", 
            "measure": "Mean change of HbA1c from Baseline to Month 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Month 12 (weeK 52)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766778"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To examine the change in FPG from baseline to Month 12", 
                "measure": "Mean change in fasting plasma glucose (FPG) from Baseline to Month 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 12 (week 52)"
            }, 
            {
                "description": "Determine percentage of patients achieving HbA1c <7.0% at month 12 between the treatment arms", 
                "measure": "Percentage of patients with HbA1c <7.0%", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }, 
            {
                "description": "Determine percentage of overall drug compliance in 12 months between treatment arms", 
                "measure": "Percentage of overall drug compliance in 12 months", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }, 
            {
                "description": "This analysis will report percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death will be reported.", 
                "measure": "Percentage patients with adverse events, serious adverse events and death as an assessment of overall safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Month 12"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}